Vatalanib (PTK787) 2HCl

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Vatalanib, also known as PTK787, is a potent vascular endothelial growth factor (VEGF) receptor tyrosine kinases inhibitor that inhibits VEGF receptor/KDR, VEGF receptor/Flt-1 and VEGF receptor/Flk with the half maximal inhibition concentration IC50 values of 0.037 μM, 0.077 μM and 0.27 μM respectively [1]. Vatalanib also inhibits other tyrosine kinases belonging to the same family of tyrosine kinase receptors as the VEGF receptors, including the platelet-derived growth factor receptor β tyrosine kinase (PDGFR-β), c-Kit and c-Fms, to a lesser degree with IC50 values of 0.58 μM, 0.73 μM and 1.4 μM respectively [1]. Vatalanib has been found to be potentially therapeutic for the treatment of angiogenesis-related diseases including solid tumors [1].
    
    [1] Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000 Apr 15;60(8):2178-89.
- Properties
  - Alternative Name
    
    N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;dihydrochloride
    
    CAS Number
    
    212141-51-0
    
    Molecular Formula
    
    C20H15ClN4·2HCl
    
    Molecular Weight
    
    419.73
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    ≥21 mg/mL in DMSO; ≥24.5 mg/mL in H2O; ≥3.41 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

Vatalanib (PTK787) 2HCl

Background

We Also Recommend

LY2835219

Mianserin HCl

PD184352 (CI-1040)